MET and cancer: Our findings suggest that crizotinib-resistant metastatic NSCLC cells can develop cellular resilience mechanisms to resist molecular or cellular perturbation by inhibition of TGFβ signaling as well as ALK and MET, providing new insight into the mechanism of cancer drug resistance.